AU2015298876B2 - Indoles for use in influenza virus infection - Google Patents
Indoles for use in influenza virus infection Download PDFInfo
- Publication number
- AU2015298876B2 AU2015298876B2 AU2015298876A AU2015298876A AU2015298876B2 AU 2015298876 B2 AU2015298876 B2 AU 2015298876B2 AU 2015298876 A AU2015298876 A AU 2015298876A AU 2015298876 A AU2015298876 A AU 2015298876A AU 2015298876 B2 AU2015298876 B2 AU 2015298876B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- amino
- nmr
- mhz
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims description 12
- 150000002475 indoles Chemical class 0.000 title description 2
- 230000009385 viral infection Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 206010022000 influenza Diseases 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims description 146
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 239000003443 antiviral agent Substances 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 229960003971 influenza vaccine Drugs 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 409
- 238000005160 1H NMR spectroscopy Methods 0.000 description 229
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 196
- 239000000203 mixture Substances 0.000 description 172
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 169
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 167
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 141
- 239000000243 solution Substances 0.000 description 134
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 109
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 104
- 238000002360 preparation method Methods 0.000 description 97
- 239000011541 reaction mixture Substances 0.000 description 95
- 239000012044 organic layer Substances 0.000 description 89
- 239000007787 solid Substances 0.000 description 89
- 239000002904 solvent Substances 0.000 description 89
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 86
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 84
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 83
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 77
- 239000012071 phase Substances 0.000 description 76
- 238000005481 NMR spectroscopy Methods 0.000 description 74
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 66
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 63
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 53
- 239000000377 silicon dioxide Substances 0.000 description 51
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 42
- 235000019341 magnesium sulphate Nutrition 0.000 description 41
- 239000000543 intermediate Substances 0.000 description 38
- 238000000746 purification Methods 0.000 description 38
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 33
- 239000012267 brine Substances 0.000 description 33
- 238000001914 filtration Methods 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 33
- 230000005526 G1 to G0 transition Effects 0.000 description 32
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 239000000706 filtrate Substances 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 29
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 239000010410 layer Substances 0.000 description 25
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- -1 elixirs Substances 0.000 description 21
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 20
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- 239000012230 colorless oil Substances 0.000 description 18
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 18
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 208000037797 influenza A Diseases 0.000 description 15
- 235000019798 tripotassium phosphate Nutrition 0.000 description 15
- 239000003643 water by type Substances 0.000 description 15
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 14
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- DEDKKOOGYIMMBC-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carbonitrile Chemical compound FC1=CC(C#N)=C(Cl)N=C1Cl DEDKKOOGYIMMBC-UHFFFAOYSA-N 0.000 description 10
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 9
- 238000004808 supercritical fluid chromatography Methods 0.000 description 9
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 9
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- 0 CC(C=*)=C(C)N* Chemical compound CC(C=*)=C(C)N* 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- MNRNSFOFHFYHNP-UHFFFAOYSA-N cyclohexane-1,3-diamine Chemical compound NC1[CH]CCC(N)C1 MNRNSFOFHFYHNP-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- ZCNXOOXHCDKUNZ-UHFFFAOYSA-N COC(C)(C)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N Chemical compound COC(C)(C)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N ZCNXOOXHCDKUNZ-UHFFFAOYSA-N 0.000 description 6
- 241000197306 H1N1 subtype Species 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 229910002666 PdCl2 Inorganic materials 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 5
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- NPPFLSSNEAIYAL-UHFFFAOYSA-N 1-(2-chloro-5-fluoropyrimidin-4-yl)cyclohexane-1,3-diamine hydrochloride Chemical compound C1CC(CC(C1)(C2=NC(=NC=C2F)Cl)N)N.Cl NPPFLSSNEAIYAL-UHFFFAOYSA-N 0.000 description 4
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N 1h-imidazole-5-carboxamide Chemical compound NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WDUDHEOUGWAKFD-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+) Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 WDUDHEOUGWAKFD-UHFFFAOYSA-N 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- OBSACSBMTRJNPH-DTWKUNHWSA-N tert-butyl n-[(1r,3s)-3-aminocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC[C@H](N)C1 OBSACSBMTRJNPH-DTWKUNHWSA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 3
- WAGLGQXOHWSQOD-UHFFFAOYSA-N 2-fluoro-6-iodo-4-methylaniline Chemical compound CC1=CC(F)=C(N)C(I)=C1 WAGLGQXOHWSQOD-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WZPOGQRJXZGSMH-UHFFFAOYSA-N 5,7-difluoro-1h-indole Chemical compound FC1=CC(F)=C2NC=CC2=C1 WZPOGQRJXZGSMH-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- BUJDXIGDEITMRG-UHFFFAOYSA-N CC1(CCCC1)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N Chemical compound CC1(CCCC1)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N BUJDXIGDEITMRG-UHFFFAOYSA-N 0.000 description 3
- IBLNNWQQKZDGQW-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1(CC(CC(C1)(C)C)N)N)F Chemical compound ClC1=NC=C(C(=N1)C1(CC(CC(C1)(C)C)N)N)F IBLNNWQQKZDGQW-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- FQQFREGJTCXKLR-UHFFFAOYSA-N FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C Chemical compound FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C FQQFREGJTCXKLR-UHFFFAOYSA-N 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 125000003963 dichloro group Chemical group Cl* 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- ZUGYJALETFVYJV-UHFFFAOYSA-N 1-methylcyclopentane-1-carbaldehyde Chemical compound O=CC1(C)CCCC1 ZUGYJALETFVYJV-UHFFFAOYSA-N 0.000 description 2
- VVXQCTFINCODIF-UHFFFAOYSA-N 2,6-dichloro-3-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC(C(F)(F)F)=C(Cl)N=C1Cl VVXQCTFINCODIF-UHFFFAOYSA-N 0.000 description 2
- AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 2
- ZQEXBVHABAJPHJ-UHFFFAOYSA-N 2-fluoro-4-methylaniline Chemical compound CC1=CC=C(N)C(F)=C1 ZQEXBVHABAJPHJ-UHFFFAOYSA-N 0.000 description 2
- ZJHBNGNAZSITGO-UHFFFAOYSA-N 2-methyl-2-(1,3-thiazol-2-yl)propanenitrile Chemical compound N#CC(C)(C)C1=NC=CS1 ZJHBNGNAZSITGO-UHFFFAOYSA-N 0.000 description 2
- FUTYAVSMXILTHT-UHFFFAOYSA-N 2-methyl-2-(1-methylpyrazol-3-yl)propanenitrile Chemical compound CN1C=CC(C(C)(C)C#N)=N1 FUTYAVSMXILTHT-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- XTGYXZZAHHTEOE-UHFFFAOYSA-N 4,4-dimethylhept-6-enoic acid Chemical compound C=CCC(C)(C)CCC(O)=O XTGYXZZAHHTEOE-UHFFFAOYSA-N 0.000 description 2
- ALVWLRRLYMWPAJ-UHFFFAOYSA-N 5-chloro-7-fluoro-1h-indole Chemical compound FC1=CC(Cl)=CC2=C1NC=C2 ALVWLRRLYMWPAJ-UHFFFAOYSA-N 0.000 description 2
- QIACATCUODRSLS-UHFFFAOYSA-N 5-methyl-1,3-oxazole-4-carboxylic acid Chemical compound CC=1OC=NC=1C(O)=O QIACATCUODRSLS-UHFFFAOYSA-N 0.000 description 2
- UVWAQDSXPNIJKF-UHFFFAOYSA-N BrC1=CN(C2=C(C=C(C=C12)F)F)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound BrC1=CN(C2=C(C=C(C=C12)F)F)S(=O)(=O)C1=CC=C(C)C=C1 UVWAQDSXPNIJKF-UHFFFAOYSA-N 0.000 description 2
- CCMVNXYIWFELQB-UHFFFAOYSA-N ClC1=CC(F)=C2NC=C(C2=C1)I Chemical compound ClC1=CC(F)=C2NC=C(C2=C1)I CCMVNXYIWFELQB-UHFFFAOYSA-N 0.000 description 2
- PYCRJCOERFXGAD-UHFFFAOYSA-N ClC1=NC=C(C(=N1)NC(CC#N)C(C)(C)C)F Chemical compound ClC1=NC=C(C(=N1)NC(CC#N)C(C)(C)C)F PYCRJCOERFXGAD-UHFFFAOYSA-N 0.000 description 2
- NXWWGWDHJHWFAZ-MNOVXSKESA-N ClC1=NC=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(C1=NC=CC=C1)=O)F Chemical compound ClC1=NC=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(C1=NC=CC=C1)=O)F NXWWGWDHJHWFAZ-MNOVXSKESA-N 0.000 description 2
- KCXHZFYNZSHRFB-UHFFFAOYSA-N ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)B1OC(C(O1)(C)C)(C)C Chemical compound ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)B1OC(C(O1)(C)C)(C)C KCXHZFYNZSHRFB-UHFFFAOYSA-N 0.000 description 2
- VNBYLAQTENYYTJ-UHFFFAOYSA-N ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)I Chemical compound ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)I VNBYLAQTENYYTJ-UHFFFAOYSA-N 0.000 description 2
- OGSBHFKFSCGLRT-UHFFFAOYSA-N FC1=C(N)C(=CC(=C1)C)C#C[Si](C)(C)C Chemical compound FC1=C(N)C(=CC(=C1)C)C#C[Si](C)(C)C OGSBHFKFSCGLRT-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- WMNOLOMGSDHERX-UHFFFAOYSA-N NC(=CC(=O)OCC)C(C)(C1=NN(C=C1)C)C Chemical compound NC(=CC(=O)OCC)C(C)(C1=NN(C=C1)C)C WMNOLOMGSDHERX-UHFFFAOYSA-N 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- JESWDXIHOJGWBP-UHFFFAOYSA-N bicyclo[2.2.1]heptane-3-carboxylic acid Chemical compound C1CC2C(C(=O)O)CC1C2 JESWDXIHOJGWBP-UHFFFAOYSA-N 0.000 description 2
- PNKGHXVHKCJNBW-UHFFFAOYSA-N bicyclo[2.2.2]octane-3-carboxylic acid Chemical compound C1CC2C(C(=O)O)CC1CC2 PNKGHXVHKCJNBW-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- MVUYVVKSXCLYSP-UHFFFAOYSA-N cyclohexane-1,3-diamine;hydrochloride Chemical compound Cl.NC1CCCC(N)C1 MVUYVVKSXCLYSP-UHFFFAOYSA-N 0.000 description 2
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- UKOFUFBBXOWCNO-UHFFFAOYSA-N methyl 3-amino-4,4-dimethylpentanoate Chemical compound COC(=O)CC(N)C(C)(C)C UKOFUFBBXOWCNO-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- AELQFRLRNCJZQE-UHFFFAOYSA-N octyl-di(propan-2-yl)silane Chemical compound CCCCCCCC[SiH](C(C)C)C(C)C AELQFRLRNCJZQE-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JNOGVQJEBGEKMG-UHFFFAOYSA-N (1-methoxy-2-methylprop-1-enoxy)-trimethylsilane Chemical compound COC(=C(C)C)O[Si](C)(C)C JNOGVQJEBGEKMG-UHFFFAOYSA-N 0.000 description 1
- JSGHMGKJNZTKGF-DTWKUNHWSA-N (1s,3r)-3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC[C@H](C(O)=O)C1 JSGHMGKJNZTKGF-DTWKUNHWSA-N 0.000 description 1
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 1
- JTWLIIMKYSVDBZ-UHFFFAOYSA-N 1-[6-[5,7-difluoro-1-(4-methylphenyl)sulfonylindol-3-yl]-3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1,3-diamine Chemical compound FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)C1=C(C=C(C(=N1)C1(CC(CCC1)N)N)F)C(F)(F)F JTWLIIMKYSVDBZ-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- WZTRQGJMMHMFGH-UHFFFAOYSA-N 1-methyl-imidazole-4-carboxylic acid Chemical compound CN1C=NC(C(O)=O)=C1 WZTRQGJMMHMFGH-UHFFFAOYSA-N 0.000 description 1
- OZYDARRKCCHJOL-UHFFFAOYSA-N 1-methylcyclopentane-1-carbonitrile Chemical compound N#CC1(C)CCCC1 OZYDARRKCCHJOL-UHFFFAOYSA-N 0.000 description 1
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 1
- ZEBFPAXSQXIPNF-UHFFFAOYSA-N 2,5-dimethylpyrrolidine Chemical compound CC1CCC(C)N1 ZEBFPAXSQXIPNF-UHFFFAOYSA-N 0.000 description 1
- QLBGFCHJCWNVIN-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)acetonitrile Chemical compound N#CCC1=NC=CS1 QLBGFCHJCWNVIN-UHFFFAOYSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 description 1
- SNBHIOPKTNPWHU-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)sulfonylindole Chemical compound CC1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=C(C)C=C1 SNBHIOPKTNPWHU-UHFFFAOYSA-N 0.000 description 1
- SYILGDLWTPODQG-UHFFFAOYSA-N 2-methyl-2-pyridin-2-ylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=CC=N1 SYILGDLWTPODQG-UHFFFAOYSA-N 0.000 description 1
- RTXFTJVXIXTDIU-UHFFFAOYSA-N 2-methyl-2-thiophen-2-ylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=CS1 RTXFTJVXIXTDIU-UHFFFAOYSA-N 0.000 description 1
- NREAWOOWYLKUED-UHFFFAOYSA-N 3-amino-4,4-dimethylpentanenitrile;hydrochloride Chemical compound Cl.CC(C)(C)C(N)CC#N NREAWOOWYLKUED-UHFFFAOYSA-N 0.000 description 1
- SNOALXYGYUOATP-UHFFFAOYSA-N 3-amino-4-methyl-4-(1-methylpyrazol-3-yl)pent-2-enoic acid Chemical compound NC(=CC(=O)O)C(C)(C1=NN(C=C1)C)C SNOALXYGYUOATP-UHFFFAOYSA-N 0.000 description 1
- RJXSLLLKTBOEEA-UHFFFAOYSA-N 3-isocyanatooxolane Chemical compound O=C=NC1CCOC1 RJXSLLLKTBOEEA-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- AZASWMGVGQEVCS-UHFFFAOYSA-N 4,4-dimethylpentan-2-one Chemical compound CC(=O)CC(C)(C)C AZASWMGVGQEVCS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- YTMYUWVMZMIXFO-UHFFFAOYSA-N 5,5-dimethylcyclohexane-1,3-diamine Chemical compound CC1(C)CC(N)CC(N)C1 YTMYUWVMZMIXFO-UHFFFAOYSA-N 0.000 description 1
- OIWNDJQQIMISPC-UHFFFAOYSA-N 5-methyl-1,3-thiazole-4-carboxylic acid Chemical compound CC=1SC=NC=1C(O)=O OIWNDJQQIMISPC-UHFFFAOYSA-N 0.000 description 1
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 description 1
- AORDVAXRGDICNT-UHFFFAOYSA-N 7-fluoro-5-methyl-1h-indole Chemical compound CC1=CC(F)=C2NC=CC2=C1 AORDVAXRGDICNT-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ULPOWWJRVSWRIN-UHFFFAOYSA-N CC(C)(C(CC(O)=O)Nc1nc(-c2c[nH]c(c(F)c3)c2cc3F)ncc1F)C(N(C)C)=O Chemical compound CC(C)(C(CC(O)=O)Nc1nc(-c2c[nH]c(c(F)c3)c2cc3F)ncc1F)C(N(C)C)=O ULPOWWJRVSWRIN-UHFFFAOYSA-N 0.000 description 1
- QWSRWKWHNGDZEH-VHSXEESVSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1Nc1nc(Cl)ncc1F)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1Nc1nc(Cl)ncc1F)=O QWSRWKWHNGDZEH-VHSXEESVSA-N 0.000 description 1
- XNYRTAKQLFILLM-UHFFFAOYSA-N CC(C)(CC(C1)NC(c2c[nH]cn2)=O)CC1Nc1nc(Cl)ncc1F Chemical compound CC(C)(CC(C1)NC(c2c[nH]cn2)=O)CC1Nc1nc(Cl)ncc1F XNYRTAKQLFILLM-UHFFFAOYSA-N 0.000 description 1
- ALHMBXWAZOZVSM-QWHCGFSZSA-N CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)c(C)cc1F)=O Chemical compound CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)c(C)cc1F)=O ALHMBXWAZOZVSM-QWHCGFSZSA-N 0.000 description 1
- DTPOISCAXTWFJM-WDEREUQCSA-N CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)ncc1F)=O Chemical compound CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)ncc1F)=O DTPOISCAXTWFJM-WDEREUQCSA-N 0.000 description 1
- GDQLRKVIULWAEQ-JRASRSEESA-N COC([C@@H](C1CCC2CC1)C2Nc1nc(Cl)ncc1F)=O Chemical compound COC([C@@H](C1CCC2CC1)C2Nc1nc(Cl)ncc1F)=O GDQLRKVIULWAEQ-JRASRSEESA-N 0.000 description 1
- LLCQYRINGDWUNV-HIFRSBDPSA-N C[C@H](CCC1)C[C@H]1Nc1nc(-c2c[n](C(OC(C)(C)C)=O)c(c(F)c3)c2cc3Cl)ncc1F Chemical compound C[C@H](CCC1)C[C@H]1Nc1nc(-c2c[n](C(OC(C)(C)C)=O)c(c(F)c3)c2cc3Cl)ncc1F LLCQYRINGDWUNV-HIFRSBDPSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N Cc(c(Cl)n1)cnc1Cl Chemical compound Cc(c(Cl)n1)cnc1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- VTWFNANUARVGQZ-CELQXHKJSA-N Cc(nc1N[C@H](CCC2)C/C2=N/C(c2ccccn2)=O)ncc1F Chemical compound Cc(nc1N[C@H](CCC2)C/C2=N/C(c2ccccn2)=O)ncc1F VTWFNANUARVGQZ-CELQXHKJSA-N 0.000 description 1
- ZCMZOMSABWKMNM-KIYNQFGBSA-N Cc1c(C(N[C@@H](CCC2)CC2Nc(nc(c(C#N)c2)Cl)c2F)=O)nc[o]1 Chemical compound Cc1c(C(N[C@@H](CCC2)CC2Nc(nc(c(C#N)c2)Cl)c2F)=O)nc[o]1 ZCMZOMSABWKMNM-KIYNQFGBSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- BDRGNLWNXYMHLZ-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)NC(CC(=O)OC)C(C)(C)C)F)C(F)(F)F Chemical compound ClC1=C(C=C(C(=N1)NC(CC(=O)OC)C(C)(C)C)F)C(F)(F)F BDRGNLWNXYMHLZ-UHFFFAOYSA-N 0.000 description 1
- XPQRUUZKRAOHDQ-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)NC(CC(=O)OCC)C(C)(C1=NN(C=C1)C)C)F)C#N Chemical compound ClC1=C(C=C(C(=N1)NC(CC(=O)OCC)C(C)(C1=NN(C=C1)C)C)F)C#N XPQRUUZKRAOHDQ-UHFFFAOYSA-N 0.000 description 1
- OCSMFOHOGTXUME-KGLIPLIRSA-N ClC1=C(C=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OCC1=CC=CC=C1)=O)F)C(F)(F)F Chemical compound ClC1=C(C=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OCC1=CC=CC=C1)=O)F)C(F)(F)F OCSMFOHOGTXUME-KGLIPLIRSA-N 0.000 description 1
- DQSBHRFBJFQRFN-UHFFFAOYSA-N ClC1=NC=C(C(=N1)NC(CC(=O)OCC)C(C)(C)C)F Chemical compound ClC1=NC=C(C(=N1)NC(CC(=O)OCC)C(C)(C)C)F DQSBHRFBJFQRFN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UMXMCLFPJZLIJJ-UHFFFAOYSA-N FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C#N Chemical compound FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C#N UMXMCLFPJZLIJJ-UHFFFAOYSA-N 0.000 description 1
- CMZIOEHDNBEXBD-UHFFFAOYSA-N FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C Chemical compound FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C CMZIOEHDNBEXBD-UHFFFAOYSA-N 0.000 description 1
- OKMLXDNGIIPDQH-UHFFFAOYSA-N FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C#N Chemical compound FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C#N OKMLXDNGIIPDQH-UHFFFAOYSA-N 0.000 description 1
- BXFWPKAXYBXUDG-UHFFFAOYSA-N FC=1C=C2C=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound FC=1C=C2C=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1 BXFWPKAXYBXUDG-UHFFFAOYSA-N 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- IGBOXGVHHSLXPE-UHFFFAOYSA-N N#CCc1n[nH]cc1 Chemical compound N#CCc1n[nH]cc1 IGBOXGVHHSLXPE-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- NFWZARAFTINKJK-QWHCGFSZSA-N N[C@@H](CCC1)C[C@@H]1NC(OCc1ccccc1)=O Chemical compound N[C@@H](CCC1)C[C@@H]1NC(OCc1ccccc1)=O NFWZARAFTINKJK-QWHCGFSZSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- NFWZARAFTINKJK-OLZOCXBDSA-N benzyl n-[(1s,3r)-3-aminocyclohexyl]carbamate Chemical compound C1[C@H](N)CCC[C@@H]1NC(=O)OCC1=CC=CC=C1 NFWZARAFTINKJK-OLZOCXBDSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- OBDWNWOYULJOBW-UHFFFAOYSA-N dimethylphosphinite dimethylphosphinous acid platinum(2+) Chemical compound [Pt++].CP(C)O.CP(C)[O-].CP(C)[O-] OBDWNWOYULJOBW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- JJOYCHKVKWDMEA-UHFFFAOYSA-N ethyl cyclohexanecarboxylate Chemical compound CCOC(=O)C1CCCCC1 JJOYCHKVKWDMEA-UHFFFAOYSA-N 0.000 description 1
- XWRLQRLQUKZEEU-UHFFFAOYSA-N ethyl(hydroxy)silicon Chemical class CC[Si]O XWRLQRLQUKZEEU-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- YSNXOQGDHGUKCZ-UHFFFAOYSA-N n-benzylhydroxylamine;hydron;chloride Chemical compound Cl.ONCC1=CC=CC=C1 YSNXOQGDHGUKCZ-UHFFFAOYSA-N 0.000 description 1
- DJOKLYSMQBPXHH-UHFFFAOYSA-N n-methyl-2-(2-trimethylsilylethynyl)aniline Chemical compound CNC1=CC=CC=C1C#C[Si](C)(C)C DJOKLYSMQBPXHH-UHFFFAOYSA-N 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- SMIQVIXGQSMHKF-UHFFFAOYSA-N oxane-3,5-dione Chemical compound O=C1COCC(=O)C1 SMIQVIXGQSMHKF-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- OBSACSBMTRJNPH-UHFFFAOYSA-N tert-butyl n-(3-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC(N)C1 OBSACSBMTRJNPH-UHFFFAOYSA-N 0.000 description 1
- XGTPDIIFEPTULX-UHFFFAOYSA-N tert-butyl prop-2-ynoate Chemical compound CC(C)(C)OC(=O)C#C XGTPDIIFEPTULX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPEP14180331.2 | 2014-08-08 | ||
| EP14180331 | 2014-08-08 | ||
| PCT/EP2015/068257 WO2016020526A1 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015298876A1 AU2015298876A1 (en) | 2017-02-02 |
| AU2015298876B2 true AU2015298876B2 (en) | 2020-02-13 |
Family
ID=51298610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015298876A Ceased AU2015298876B2 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10597390B2 (enExample) |
| EP (1) | EP3177609A1 (enExample) |
| JP (1) | JP6577570B2 (enExample) |
| KR (1) | KR102488479B1 (enExample) |
| CN (1) | CN106573920B (enExample) |
| AU (1) | AU2015298876B2 (enExample) |
| BR (1) | BR112017002370B1 (enExample) |
| CA (1) | CA2954751C (enExample) |
| CL (1) | CL2017000309A1 (enExample) |
| EA (1) | EA201790266A1 (enExample) |
| IL (1) | IL250408B (enExample) |
| MA (1) | MA40547A (enExample) |
| MX (1) | MX381488B (enExample) |
| PH (1) | PH12017500207B1 (enExample) |
| SG (1) | SG11201700956VA (enExample) |
| UA (1) | UA124609C2 (enExample) |
| WO (1) | WO2016020526A1 (enExample) |
| ZA (1) | ZA201700952B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI483941B (zh) | 2009-06-17 | 2015-05-11 | Vertex Pharma | 流感病毒複製之抑制劑 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| SG11201700956VA (en) | 2014-08-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| AU2016368317B2 (en) | 2015-12-09 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| SI3400225T1 (sl) * | 2016-01-07 | 2022-01-31 | Janssen Sciences Ireland Unlimited Company | Pentanojske kisline substituirane s pirolo-(2-3,b)pirimidin-piridini za zdravljenje okužb z virusom gripe |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| US10501444B2 (en) | 2016-08-16 | 2019-12-10 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) * | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| CA3035680C (en) * | 2016-09-05 | 2023-05-02 | Jian Xiong | Anti-influenza virus pyrimidine derivatives |
| AU2017376541B2 (en) | 2016-12-15 | 2021-08-05 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CA3047404A1 (en) | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| CN108276401B (zh) | 2017-01-05 | 2020-12-22 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| US10927118B2 (en) | 2017-03-02 | 2021-02-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| NZ767352A (en) * | 2018-03-05 | 2023-05-26 | Guangdong Raynovent Biotech Co Ltd | Crystal form and salt form of pyridopyrazole compound and preparation method therefor |
| EP3992192A4 (en) * | 2019-07-22 | 2022-08-17 | Guangdong Raynovent Biotech Co., Ltd. | DOMINANT SALT FORMS OF PYRIMIDINE DERIVATIVES AND CRYSTAL FORMS THEREOF |
| CN113045475A (zh) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | 一种5-溴-7-甲基吲哚的制备方法 |
| IL299989A (en) * | 2020-07-20 | 2023-03-01 | Nido Biosciences Inc | Indole compounds as androgen receptor modulators |
| WO2022057842A1 (en) * | 2020-09-18 | 2022-03-24 | Sunshine Lake Pharma Co., Ltd. | Preparation method of substituted pyrimidine piperazine compounds |
| CR20250176A (es) * | 2022-10-12 | 2025-06-25 | Maze Therapeutics Inc | Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y métodos de uso de los mismos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083122A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) * | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101298967B1 (ko) | 2004-03-30 | 2013-09-02 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
| RU2453548C2 (ru) | 2006-01-17 | 2012-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Азаиндолы, полезные в качестве ингибиторов янус-киназ |
| TWI483941B (zh) * | 2009-06-17 | 2015-05-11 | Vertex Pharma | 流感病毒複製之抑制劑 |
| JP5876051B2 (ja) * | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体 |
| MX2013006836A (es) * | 2010-12-16 | 2013-09-26 | Vertex Pharma | Inhibidores de la replicacion de los virus de la influenza. |
| RU2673064C2 (ru) | 2011-09-01 | 2018-11-22 | Ф. Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| EP2858984A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Inc. | Inhibitors of influenza viruses replication |
| SMT201900450T1 (it) | 2013-11-13 | 2019-09-09 | Vertex Pharma | Inibitori della replicazione di virus dell’influenza |
| AR101401A1 (es) | 2014-08-08 | 2016-12-14 | Bayer Cropscience Ag | Derivados de bipirazol, sustituidos con halógeno |
| UY36255A (es) | 2014-08-08 | 2016-01-29 | Bayer Cropscience Ag | Compuestos sustituidos por halógeno novedosos |
| SG11201700956VA (en) | 2014-08-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| CN104592038A (zh) | 2015-01-12 | 2015-05-06 | 烟台万润精细化工股份有限公司 | 一种5,5-二甲基-1,3-环己二胺的制备方法 |
-
2015
- 2015-08-07 SG SG11201700956VA patent/SG11201700956VA/en unknown
- 2015-08-07 MA MA040547A patent/MA40547A/fr unknown
- 2015-08-07 WO PCT/EP2015/068257 patent/WO2016020526A1/en not_active Ceased
- 2015-08-07 UA UAA201702154A patent/UA124609C2/uk unknown
- 2015-08-07 US US15/501,730 patent/US10597390B2/en not_active Expired - Fee Related
- 2015-08-07 BR BR112017002370-9A patent/BR112017002370B1/pt not_active IP Right Cessation
- 2015-08-07 AU AU2015298876A patent/AU2015298876B2/en not_active Ceased
- 2015-08-07 EP EP15750365.7A patent/EP3177609A1/en not_active Withdrawn
- 2015-08-07 MX MX2017001752A patent/MX381488B/es unknown
- 2015-08-07 KR KR1020177005979A patent/KR102488479B1/ko active Active
- 2015-08-07 EA EA201790266A patent/EA201790266A1/ru unknown
- 2015-08-07 JP JP2017506964A patent/JP6577570B2/ja not_active Expired - Fee Related
- 2015-08-07 CA CA2954751A patent/CA2954751C/en active Active
- 2015-08-07 CN CN201580042406.9A patent/CN106573920B/zh not_active Expired - Fee Related
-
2017
- 2017-02-02 PH PH12017500207A patent/PH12017500207B1/en unknown
- 2017-02-02 IL IL250408A patent/IL250408B/en active IP Right Grant
- 2017-02-07 CL CL2017000309A patent/CL2017000309A1/es unknown
- 2017-02-07 ZA ZA2017/00952A patent/ZA201700952B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083122A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) * | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017000309A1 (es) | 2017-08-18 |
| UA124609C2 (uk) | 2021-10-20 |
| SG11201700956VA (en) | 2017-03-30 |
| US20170226102A1 (en) | 2017-08-10 |
| CA2954751A1 (en) | 2016-02-11 |
| KR20170039275A (ko) | 2017-04-10 |
| CN106573920A (zh) | 2017-04-19 |
| WO2016020526A1 (en) | 2016-02-11 |
| KR102488479B1 (ko) | 2023-01-12 |
| IL250408B (en) | 2020-08-31 |
| IL250408A0 (en) | 2017-03-30 |
| CN106573920B (zh) | 2020-11-10 |
| MA40547A (fr) | 2017-06-14 |
| BR112017002370A2 (pt) | 2017-12-05 |
| MX381488B (es) | 2025-03-12 |
| CA2954751C (en) | 2023-01-17 |
| ZA201700952B (en) | 2018-12-19 |
| EA201790266A1 (ru) | 2017-06-30 |
| PH12017500207A1 (en) | 2017-07-10 |
| MX2017001752A (es) | 2018-02-08 |
| PH12017500207B1 (en) | 2017-07-10 |
| AU2015298876A1 (en) | 2017-02-02 |
| EP3177609A1 (en) | 2017-06-14 |
| JP6577570B2 (ja) | 2019-09-18 |
| JP2017523225A (ja) | 2017-08-17 |
| US10597390B2 (en) | 2020-03-24 |
| BR112017002370B1 (pt) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015298876B2 (en) | Indoles for use in influenza virus infection | |
| KR102531340B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘 | |
| AU2017209925B2 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| ES2882671T3 (es) | Indoles heterocíclicos para su uso en infecciones por el virus de la gripe | |
| AU2012290127A1 (en) | Inhibitors of influenza viruses replication | |
| EP3746444A1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv | |
| HK1236532B (zh) | 用於在流感病毒感染中使用的吲哚 | |
| HK1236532A1 (en) | Indoles for use in influenza virus infection | |
| CA3005921A1 (en) | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication | |
| OA19823A (en) | Inhibitors of influenza viruses replication. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |